What we've found so far is that MCP-1 levels appear to be higher in patients undergoing CABG (coronary artery bypass graft) surgery compared to those having aortic valve surgery. The evidence we've reviewed leans toward this pattern, based on the data currently available [1].
Our analysis of the research shows that patients undergoing CABG surgery tend to have notably higher levels of MCP-1, a protein involved in inflammation and immune cell activity, than those receiving aortic valve surgery [1]. This difference may reflect the underlying state of inflammation associated with coronary artery disease, which is typically more widespread in the blood vessels and may trigger a stronger immune response. Since MCP-1 helps recruit immune cells to sites of inflammation, elevated levels could indicate greater immune system involvement in patients with advanced atherosclerosis, the condition often requiring bypass surgery [1].
It’s important to note that while the evidence we’ve analyzed supports this trend, we are basing our current understanding on a limited number of claims—just one distinct finding, which has been cited across multiple studies (totaling 27.0 supporting instances, 0 refuting) [1]. We don’t yet have enough comparative studies to fully understand the size or causes of this difference, nor do we know how these levels might affect recovery or long-term outcomes.
Based on what we’ve reviewed so far, the body’s inflammatory response, as measured by MCP-1, seems to differ between these two types of heart surgery, with higher levels linked to CABG. However, we can’t yet say how much of this difference is due to the surgery itself versus the underlying disease.
Practical takeaway: If you’re having heart surgery, the type of procedure you need might be linked to different levels of inflammation in your body—something that could matter for recovery, but more research is needed to know exactly how.
2 items of evidenceView full answer